Novartis med gets nod for fracture prevention

SPOTLIGHT: Novartis med gets nod for fracture prevention
Novartis said the FDA approved its bone-building drug Reclast as a treatment to prevent additional fractures following a hip fracture; the once-yearly drug's revised label includes data showing a 35 percent reduction in follow-up fractures. Report